Abstract: The invention relates to an apparatus and method of detecting and quantifying the number of circulating tumour cells (CTCs) and/or tumour cells (TCs) from a liquid biopsy by using a hyperoxic environment and incubation with a fluorophore-labelled metabolic indicator (fluorophore-labelled 2-D-glucose derivative) and microfluidic chips.
Abstract: A method and a system for detection of presence or absence of analytes in fluids, the method comprising the steps of: a) contacting a fluid sample and a plurality of nanoparticles, the nanoparticles being functionalized with a selective ligand, the contact of the fluid sample with the nanoparticles being under conditions such that, the nanoparticles aggregate selectively on surface of their target analyte, forming a nanoparticle-analyte complex, the aggregation promoting the concentration of the nanoparticles on the surface of the target analyte; b) subjecting a fluid mixture of the fluid sample and the plurality of nanoparticles to SERS; c) measuring at least a SERS signal associated with the fluid mixture; d) spectrally analyzing the at least one SERS signal of step c); e) recognizing at least one defined SERS spectrum of the nanoparticle-analyte complex, through a SERS signal enhanced by the at least one narrow inter-nanoparticle gap.
Type:
Grant
Filed:
July 31, 2015
Date of Patent:
June 18, 2019
Assignees:
Medcom Advance, S.A, Universitat Rovira i Virgili, Fundació Privada Centre Tecnologic de la Química de Catalunya, Fundació Privada Institutio Catalana de Recerca I Estudis Avançats, Medcom Tech, S.A
Inventors:
Nicolás Pazos-Pérez, Elena Pazos, Carme Catala, Bernat Mir-Simón, Sara Gomez-De-Pedro, Juan Sagales, Carlos Villanueva, Ramon A. Alvarez-Puebla